Indian Firm Seeks To Prove New Drugs Can Be Developed Cheaply
This article was originally published in PharmAsia News
An investment company in India has poured more than $61 million into five companies as part of an effort to prove drug development can be done more cheaply than is the practice today. Nadathur Holdings and Investments says it seeks to disprove the assumption new-drug development requires as much as $1 billion. Nadathur has created Lifespring Ventures as a subsidiary, now owner itself of five start-up firms in the drug-discovery process. The firms operate as stand-alone companies trying to find treatments focusing on metabolic syndrome connected to heart, stroke and diabetes conditions. (Click here for more
You may also be interested in...
Mexico's Genomma Lab recorded strong double-digit growth for its OTC business in the second quarter as sales more than doubled at its US consumer health operation.
New board directors named at Autolus Therapeutics, Beximco Pharmaceuticals, Tetraphase Pharmaceuticals and Vesigen.
After launching a biosimilar to Avastin (bevacizumab) in India, Cadila Pharma has now also launched rituximab and teriparatide biosimilars in its domestic market.